These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 29025978)

  • 1. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G
    J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Lisi L; Bonanno E; Scimeca M; Eskilsson E; Daubon T; Miletic H; Ricci Vitiani L; Pallini R; Navarra P; Bjerkvig R; D'Atri S; Lacal PM; Graziani G
    J Exp Clin Cancer Res; 2017 Aug; 36(1):106. PubMed ID: 28797294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.
    Lacal PM; Atzori MG; Ruffini F; Tentori L; Graziani G
    Oncol Rep; 2018 May; 39(5):2261-2269. PubMed ID: 29512738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
    Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
    J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor.
    Atzori MG; Ceci C; Ruffini F; Scimeca M; Cicconi R; Mattei M; Lacal PM; Graziani G
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
    Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
    MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
    Wu Y; Hooper AT; Zhong Z; Witte L; Bohlen P; Rafii S; Hicklin DJ
    Int J Cancer; 2006 Oct; 119(7):1519-29. PubMed ID: 16671089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
    Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
    Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study.
    Zhou YX; Huang YL
    Chin Med J (Engl); 2009 Jul; 122(14):1666-73. PubMed ID: 19719969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
    Kimura Y; Sumiyoshi M; Baba K
    Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.